Ann: Update on Submission of Final Module to FDA, page-34

Just a small correction to my “nowhere near the heart” statement. Obviously the transmitter and battery are close enough for the ultrasonic signals to activate the implanted electrode inside the left ventricle.

Given EBR’s willingness to explain technical issues, one feels the company will elaborate on the context of the current delay to the testing schedule. But the President and CEO has already publicly stated:

“We believe the benefits from additional testing have the potential to demonstrate increased durability of the WiSE CRT device, resulting in a more robust PMA submission.”